CIK 0001437402
- Large accelerated filer
ARDELYX, INC.
Sign in to watch- Ticker
- ARDX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 510-745-7047
- Business address
- 34175 ARDENWOOD BLVD., FREMONT, CA, 94555
- Former names
- NTERYX INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $486,197
- in 8 filings
Net −$486,197. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- RAAB MICHAEL −$226K President & CEO sold 3% of stake
- Bishop John E −$76K Reporting owner sold 6% of stake
- Brady James Parker −$58K Chief Human Resources Officer sold 6% of stake
- Williams Laura A −$41K Chief Patient Officer sold 3% of stake
- Foster Eric Duane −$33K Chief Commercial Officer sold 2% of stake
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-01-16 | Rosenbaum David P. Chief Development Officer | Grant or award | +112,750 | 399,346 | ||
| 2024-01-16 | Rosenbaum David P. Chief Development Officer | Grant or award | +70,120 | 183,413 | ||
| 2024-01-16 | Rosenbaum David P. Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +145,000 | 145,000 | ||
| 2024-01-16 | Rosenbaum David P. Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +99,000 | 99,000 | ||
| 2024-01-16 | Rodriguez Susan Chief Commercial Officer | Grant or award | +112,750 | 459,723 | ||
| 2024-01-16 | Rodriguez Susan Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +145,000 | 145,000 | ||
| 2024-01-16 | Renz Justin A Chief Financial Officer | Grant or award | +127,750 | 310,176 | ||
| 2024-01-16 | Renz Justin A Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +164,000 | 164,000 | ||
| 2024-01-16 | RAAB MICHAEL President & CEO | Grant or award | +475,000 | 1,342,868 | ||
| 2024-01-16 | RAAB MICHAEL President & CEO | Grant or award · Stock Option (Right to Buy) | +605,904 | 605,904 | ||
| 2024-01-16 | GRAMMER ELIZABETH A | Grant or award | +127,750 | 403,425 | ||
| 2024-01-16 | GRAMMER ELIZABETH A | Grant or award · Stock Option (Right to Buy) | +164,000 | 164,000 | ||
| 2024-01-16 | Felsch Robert Ora | Grant or award | +70,120 | 187,186 | ||
| 2024-01-16 | Felsch Robert Ora | Grant or award · Stock Option (Right to Buy) | +99,000 | 99,000 | ||
| 2024-01-16 | Blanks Robert | Grant or award | +112,750 | 373,203 | ||
| 2024-01-16 | Blanks Robert | Grant or award · Stock Option (Right to Buy) | +145,000 | 145,000 | ||
| 2024-01-08 | Rosenbaum David P. Chief Development Officer | Sale 10b5-1 | −30,000 | $6.64 | $199K | 286,596 |
| 2023-12-26 | Renz Justin A Chief Financial Officer | Exercise or conversion 10b5-1 | +75,000 | $0.99 | $74K | 407,426 |
| 2023-12-26 | Renz Justin A Chief Financial Officer | Sale 10b5-1 | −225,000 | $6.36 | $1.4M | 182,426 |
| 2023-12-26 | Renz Justin A Chief Financial Officer | Exercise or conversion · Stock Option (Right to Buy) 10b5-1 | −75,000 | 121,000 |
Page 17 of 18 · 360 trades